Abstract
Oxysterols are pleiotropic messengers interacting with multiple receptor systems. One of the cognate receptors for oxysterols is EBI2, a G protein-coupled receptor highly expressed in the cells of the immune system. Here we discuss the receptor’s role in the adapted immunity and inflammation as well as the receptor’s expression and function in the CNS with the focus on astrocytes. We also discuss expression and signalling of oxysterol-producing enzymes such as CH25H and CYP7B1 in the CNS and the immune system. These steps will help to elucidate a possible role for this pathway in the physiology of the central and peripheral nervous system and its possible link to human disease.
Keywords: Astrocytes, autoimmunity, central nervous system, EBI2, immune system, neurodegeneration, oligodendrocytes.
Graphical Abstract
Current Drug Targets
Title:The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Volume: 17 Issue: 16
Author(s): Aleksandra Rutkowska, Kumlesh K. Dev and Andreas W. Sailer
Affiliation:
Keywords: Astrocytes, autoimmunity, central nervous system, EBI2, immune system, neurodegeneration, oligodendrocytes.
Abstract: Oxysterols are pleiotropic messengers interacting with multiple receptor systems. One of the cognate receptors for oxysterols is EBI2, a G protein-coupled receptor highly expressed in the cells of the immune system. Here we discuss the receptor’s role in the adapted immunity and inflammation as well as the receptor’s expression and function in the CNS with the focus on astrocytes. We also discuss expression and signalling of oxysterol-producing enzymes such as CH25H and CYP7B1 in the CNS and the immune system. These steps will help to elucidate a possible role for this pathway in the physiology of the central and peripheral nervous system and its possible link to human disease.
Export Options
About this article
Cite this article as:
Rutkowska Aleksandra, Dev K. Kumlesh and Sailer W. Andreas, The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems, Current Drug Targets 2016; 17 (16) . https://dx.doi.org/10.2174/1389450117666160217123042
DOI https://dx.doi.org/10.2174/1389450117666160217123042 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Synthesis of a Tyr-Tyr Dipeptide Library and Evaluation Against Tumor Cells
Medicinal Chemistry CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia
Current Cancer Drug Targets Poly(ADP-ribose)polymerase Inhibition - Where Now?
Current Medicinal Chemistry A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Anti-Cancer Agents in Medicinal Chemistry Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Current Cancer Drug Targets Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children
Current Drug Safety Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets